A NOVEL ANGIOGENESIS INHIBITOR BEVACIZUMAB
INDUCES APOPTOSIS IN THE RAT ENDOMETRIOSIS MODEL
Soysal D1,*, Kızıldağ S2,*, Saatlı B1, Posacı C1, Soysal S3, Koyuncuoğlu M4, Doğan ÖE1
*Corresponding Author: Sefa Kızıldağ, Ph.D., Dokuz Eylül University, Faculty of Medicine, 35340 İnciralti,
İzmir, Turkey. Tel.: +90-2324124613. Fax: +90-2322590541. E-mail:sefa.kizildag@deu.edu.tr
page: 73
|
|
REFERENCES
1. Eskenazi B, Warner ML. Epidemiology of endometriosis.
Obstet Gynecol Clin North Am. 1997;
24(2): 235-258.
2 D’Hooghe TM, Debrock S, Hill JA, Meuleman
C. Endometriosis and subfertility: Is the relationship
resolved? Semin Reprod Med 2003; 21(2):
243-254.
3. Vinatier D, Orazi G, Cosson M, Dufour P. Theories
of endometriosis. Eur J Obstet Gynecol Reprod
Biol. 2001; 96(1): 21-34.
4. McLaren J. Vascular endothelial growth factor
and endometriotic angiogenesis. Hum Reprod
Update. 2000; 6(1): 45-55.
5. Grothey A, Ellis LM. Targeting angiogenesis
driven by vascular endothelial growth factors
using antibody-based therapies. Cancer J. 2008;
14(3):170-177.
6. Selvakumaran M, Yao KS, Feldman MD,
O’Dwyer PJ. Antitumor effect of the angiogenesis
inhibitor bevacizumab is dependent on susceptibility
of tumors to hypoxia-induced apoptosis.
Biochem Pharmacol. 2008; 75(3): 627-638.
7. Carmeliet P, Dor Y, Herbert JM, Fukumura D,
Brusselmans K, Dewerchin M, et al. Role of HIF-
1α in hypoxia-mediated apoptosis, cell proliferation
and tumour angiogenesis. Nature. 1998;
394(6692): 485-490.
8. Shaheen RM, Davis DW, Liu W, Zebrowski BK,
Wilson MR, Bucana CD, et al. Antiangiogenic
therapy targeting the tyrosine kinase receptor for
vascular endothelial growth factor receptor inhibits
the growth of colon cancer liver metastasis
and induces tumor and endothelial cell apoptosis.
Cancer Res. 1999; 59(21): 5412-5416.
9. Gebel HM, Braun DP, Tambur A, Frame D, Rana
N, Dmowski WP. Spontaneous apoptosis of endometrial
tissue is impaired in women with endometriosis.
Fertil Steril. 1998; 69(6): 1042-1047.
10. Safaeian L, Abed A, Vaseghi G. The role of Bcl-
2 family proteins in pulmonary fibrosis. Eur J
Pharmacol. 2014. pii: S0014-2999(14)00566-4.
doi: 10.1016/j.ejphar. 2014.07.029.
11. Tesone M, Bilotas M, Barañao RI, Meresman G.
The role of GnRH analogues in endometriosisassociated
apoptosis and angiogenesis. Gynecol
Obstet Invest. 2008; 66(Suppl 1): 10-18.
12. Vernon MW, Wilson EA. Studies on the surgical
induction of endometriosis in the rat. Fertil Steril.
1985; 44(5): 684-694.
13. Linsky CB, Diamond MP, Cunningham T, Constantine
B, De-Cherney AH, diZerega GS. Adhesion
reduction in a rabbit uterine horn model
using an absorbable barrier TC-7. J Reprod Med.
1987; 32(1): 17-20.
14. Keenan JA, Williams-Boyce PK, Massey PJ,
Chen TT, Caudle MR, Bukovsky A. Regression
of endometrial explants in a rat model of endometriosis
treated with the immune modulators
loxoribine and levamisole. Fertil Steril. 1999;
72(1): 135-141.
15. Crosignani P, Olive D, Bergqvist A, Luciano A.
Advances in the management of endometriosis:
An update for clinicians. Hum Reprod Update.
2006; 12(2): 179-189.
16. Matsuzaki S, Canis M, Murakami T, Dechelotte
P, Bruhat MA, Okamura K. Immunohistochemical
analysis of the role of angiogenic status in the
vasculature of peritoneal endometriosis. Fertil
Steril. 2001; 76(4): 712-716.
17. Mihalyi A, Simsa P, Mutinda KC, Meuleman C,
Mwenda JM, D’Hooghe TM. Emerging drugs in
endometriosis. Expert Opin Emerg Drugs. 2006;
11(3): 503-524.
18. Rice VM. Conventional medical therapies for
endometriosis. Ann N Y Acad Sci. 2002; 955:
343-352.
19. Child TJ, Tan SL. Endometriosis: Aetiology,
pathogenesis and treatment. Drugs. 2001; 61(12):
1735-1750.
20. Groothuis PG, Nap AW, Winterhager E, Grümmer
R. Vascular development in endometriosis.
Angiogenesis. 2005; 8(2): 147-156.
21. Donnez J, Smoes P, Gillerot S, Casanas-Roux F,
Nisolle M. Vascular endothelial growth factor
(VEGF) in endometriosis. Hum Reprod. 1998;
13(6): 1686-1690.
22. Taylor RN, Lebovic DI, Mueller MD. Angiogenic
factors in endometriosis. Ann N Y Acad
Sci. 2002; 955: 89-100.
23. Nisolle M, Casanas-Roux F, Anaf V, Mine JM,
Donnez J. Morphometric study of the stromal
vascularization in peritoneal endometriosis. Fertil
Steril. 1993; 59(3):681-684.
24. Matsuzaki S, Canis M, Murakami T, Dechelotte
P, Bruhat MA, Okamura K. Immunohistochemical
analysis of the role of angiogenic status in the
vasculature of peritoneal endometriosis. Fertil
Steril. 2001; 76(4):712-716.
25. Hull ML, Charnock-Jones DS, Chan CL, Bruner-
Tran KL, Osteen KG, Tom BD, et al. Antiangiogenic
agents are effective inhibitors of endometriosis.
J Clin Endocrinol Metab. 2003; 88(6):
2889-2899.
26. Dabrosin C, Gyorffy S, Margetts P, Ross C,
Gauldie J. Therapeutic effect of angiostatin gene
transfer in a murine model of endometriosis. Am
J Pathol. 2002; 161(3): 909-918.
27. Nap AW, Griffioen AW, Dunselman GA, Bouma-
Ter Steege JC, Thijssen VL, Evers JL, et al. Antiangiogenesis
therapy for endometriosis. J Clin
Endocrinol Metab. 2004; 89(3): 1089-1095.
28. Becker CM, Sampson DA, Rupnick MA, Rohan
RM, Efstathiou JA, Short SM, et al. Endostatin
inhibits the growth of endometriotic lesions
but does not affect fertility. Fertil Steril. 2005;
84(Suppl 2): 1144-1155.
29. Laschke MW, Elitzsch A, Vollmar B, Vajkoczy
P, Menger MD. Combined inhibition of vascular
endothelial growth factor (VEGF), fibroblast
growth factor and platelet-derived growth factor,
but not inhibition of VEGF alone, effectively
suppresses angiogenesis and vessel maturation
in endometriotic lesions. Hum Reprod. 2006;
21(1): 262-268.
30. Novella-Maestre E, Carda C, Noguera I, Ruiz-
Saurí A, García-Velasco JA, Simón C, et al. Dopamine
agonist administration causes a reduction
in endometrial implants through modulation of
angiogenesis in experimentally induced endometriosis.
Hum Reprod. 2009; 24(5): 1025-1035.
31. Ricci AG, Olivares CN, Bilotas MA, Meresman
GF, Barañao RI. Effect of vascular endothelial
growth factor inhibition on endometrial implant
development in a murine model of endometriosis.
Reprod Sci. 2011; 18(7): 614-622.
32. Meresman GF, Bilotas MA, Lombardi E, Tesone
M, Sueldo C, Baranao R. Effect of GnRH analogues
on apoptosis and release of interleukin-1β
and vascular endothelial growth factor in endometrial
cell cultures from patients with endometriosis.
Hum Reprod. 2003; 18(9): 1767-1771.
33. Bilotas M, Barañao RI, Buquet R, Sueldo C, Tesone
M, Meresman GF. Effect of GnRH analogues
on apoptosis and expression of Bcl-2, Bax, Fas
and FasL proteins in endometrial epithelial cell
cultures from patients with endometriosis and
controls. Hum Reprod. 2007; 22(3): 644-653.
34. Meresman GF, Bilotas M, Buquet RA, Barañao
RI, Sueldo C, Tesone M. Gonadotropin-releasing
hormone agonist induces apoptosis and reduces
cell proliferation in eutopic endometrial cultures
from women with endometriosis. Fertil Steril.
2003; 80(2): 702-707.
35. Imai A, Takagi A, Tamaya T. Gonadotropin-releasing
hormone analog repairs reduced endometrial
cell apoptosis in endometriosis in vitro. Am
J Obstet Gynecol. 2000; 182(5): 1142-1146.
36. Khan KN, Kitajima M, Hiraki K, Fujishita A,
Sekine I, Ishimaru T, et al. Changes in tissue
inflammation, angiogenesis and apoptosis in endometriosis,
adenomyosis and uterine myoma
after GnRH agonist therapy. Hum Reprod. 2010;
25(3): 642-653.
37. Moraloğlu O, Işik H, Kiliç S, Sahin U, Caydere
M, Ustün H, et al. Effect of bevacizumab on postoperative
adhesion formation in a rat uterine horn
adhesion model and the correlation with vascular
endothelial growth factor and Ki-67 immunopositivity.
Fertil Steril. 2011; 95(8): 2638-2641.
38. Shord SS, Bressler LR, Tierney LA, Cuellar S,
George A. Understanding and managing the possible
adverse effects associated with bevacizumab.
Am J Health Syst Pharm. 2009; 66(11): 999-101.
|
|
|
|
 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
|
